Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

INTRODUCTION: The efficacy of pegloticase, a polyethylene glycol (PEG)-conjugated mammalian recombinant uricase, approved for chronic refractory gout, can be limited by the development of antibodies (Ab). Analyses from 2 replicate, 6-month, randomized controlled trials were performed to characterize...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipsky, Peter E, Calabrese, Leonard H, Kavanaugh, Arthur, Sundy, John S, Wright, David, Wolfson, Marsha, Becker, Michael A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060440/
https://www.ncbi.nlm.nih.gov/pubmed/24588936
http://dx.doi.org/10.1186/ar4497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060440/
https://www.ncbi.nlm.nih.gov/pubmed/24588936
http://dx.doi.org/10.1186/ar4497

Ejemplares similares